Clovis Oncology, Inc. (NASDAQ:CLVS) went up by 5.54% from its latest closing price when compared to the 1-year high value of $50.00 and move down -269.82%, while CLVS stocks collected -6.37% of loss with the last five trading sessions.
Clovis Oncology, Inc. (NASDAQ:CLVS) Worth an Investment?
Clovis Oncology, Inc. (NASDAQ: CLVS) The 36 Months beta value for CLVS stocks is at 1.86, while 8 of the analysts out of 11 who provided ratings for Clovis Oncology, Inc. stocks as a “buy” while 0 as overweight, 2 rated it as hold and 1 as sell. The average price we get from analysts is $28.20 which is $15.98 above current price. CLVS currently has a short float of 17.26% and public float of 49.9M with average trading volume of 1.50M shares.
CLVS Market Performance
CLVS stocks went down by -6.37% for the week, with the monthly drop of -14.97% and a quarterly performance of -44.50%, while its annual performance rate touched -69.85%. The simple moving average for the period of the last 20 days is -4.79% for CLVS stocks with the simple moving average of -38.66% for the last 200 days.
Analysts’ Opinion on Clovis Oncology, Inc. (NASDAQ:CLVS)
Many brokerage firms have already submitted their reports for CLVS stocks, with Goldman repeating the rating for CLVS shares by setting it to “Sell”. The predicted price for CLVS socks in the upcoming period according to Goldman is $4 based on the research report published on May 29, 2019.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see CLVS stock at the price of $37, previously predicting the value of $39. The rating they have provided for CLVS stocks is “Buy” according to the report published on April 15, 2019.
H.C. Wainwright gave “Buy” rating to CLVS stocks, setting the target price at $40 in the report published on February 13, 2019.
CLVS Stocks -19.79% Far from 50 Day Moving Average
After a stumble in the market that brought CLVS to its low price for the period of the last 52 weeks, Clovis Oncology, Inc. was unable to take a rebound, for now settling with -72.96% of loss for the given period.
The stock volatility was left at 6.72%, however, within the period of a single month, the volatility rate increased by 8.58%, while the shares sank at the distance of -9.93% for the moving average in the last 20 days. In oppose to the moving average for the last 50 days, trading by -36.26% lower at the present time.
In the course of the last 5 trading sessions, CLVS went down by -6.37%, which changed the moving average for the period of 200 days to the total of -61.71% of losses for the stock in comparison to the 20-day moving average settled at $14.13. In addition, Clovis Oncology, Inc. saw -24.72% in overturn over the period of a single year with a tendency to cut further losses.
CLVS Stock Insider Trading
Reports are indicating that there were more than several insider trading activities at Clovis Oncology, Inc. (CLVS), starting from Rolfe Lindsey, who sold 1,728 shares at the price of $14.70 back on Jun 20. After this action, Rushing now owns 21,591 shares of Clovis Oncology, Inc., valued at $25,402 with the latest closing price.
IVERS-READ GILLIAN C, the See Remarks of Clovis Oncology, Inc., sold 829 shares at the value of $14.70 during a trade that took place back on Jun 20, which means that IVERS-READ GILLIAN C is holding 191,788 shares at the value of $12,186 based on the most recent closing price.
CLVS Stock Fundamentals
The current profitability levels are settled at -349.95 for the present operating margin and +76.86 for gross margin. The net margin for Clovis Oncology, Inc. stands at -385.80. Total capital return value is set at -47.86, while invested capital returns managed to touch -53.65. Equity return holds the value -196.40%, with -43.00% for asset returns.
Based on Clovis Oncology, Inc. (CLVS), the company’s capital structure generated 393.60 points for debt to equity in total, while total debt to capital is set at the value of 79.74. Total debt to assets is settled at the value of 66.62 with long-term debt to equity ratio rests at 392.90 and long-term debt to capital is 79.60.
The value for Enterprise to Sales is 7.76 with debt to enterprise value settled at 0.58. The receivables turnover for Clovis Oncology, Inc. is 8.16 with the total asset turnover at the value of 0.12. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.55.